The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer
Status:
Unknown status
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
Pancreatic cancer is a very poor prognosis and has a high mortality rate. The clinical
results have improved somewhat with the combination therapy of chemotherapy as the first-line
treatment. However, effective secondary chemotherapy after these first-line treatment
failures is limited. Recently, FOLFIRINOX has been used in patients with locally advanced or
metastatic pancreatic cancer who have good performance in Korea. Gemcitabine + nab-paclitaxel
(GnP) as a second-line treatment after FOLFIRINOX may be expected to be considerable. The aim
of this study was to evaluate the efficacy of GnP as a second-line treatment after failed
FOLFIRINOX treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma.